Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06680089 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD70-targeted immunoPET Imaging of Kidney Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Phase: Not applicable to Phase 2v3 Show 6 more changesShow less
    • Start date: Aug 1, 2024 to Nov 27, 2024
    • Primary endpoints revised (5)
    • Primary completion date: Aug 2026 to Nov 2026
    • Study completion date: Aug 2026 to Nov 2027
    • Secondary endpoints: 2 to 1
    • Study description expanded, about 20 words
  2. Eligibility criteria shortened, about 53 words
    • Study description expanded, about 73 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RenJi Hospital
190 trials monitored
See 2 trials at risk
Kidney Cancer
889 trials monitored
See 68 trials at risk
The aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.
Trial Details
NCT Number NCT06680089
Lead Sponsor RenJi Hospital
Conditions
(from sponsor)		 Urologic Neoplasms, Urogenital Neoplasms, Kidney Neoplasms, Neoplasms
Related terms Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms, Urogenital Neoplasms, Urologic Neoplasms
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov